Prior to Persona Biome, Dr. Weiss was founding Chief Medical Officer at AOBiome where he formulated AOB-101, the first live topical biotherapeutic and ran the first successful virtual Phase IIb clinical trial. He also developed the Mother Dirt cosmetic line, including AO Mist, the first live skin probiotic. He has an extensive background in natural products chemistry, microbiology, clinical medicine, dermatology, anesthesiology, biophysics, and pharmaceutical and cosmetic product development. Dr. Weiss is board certified in Anesthesiology, has an MD from Stanford University, and a BS in Biochemistry from Cornell University. He has 14 patents and is published in the areas of chemistry, electrophysiology, clinical pharmacology, and the microbiome. Dr. Weiss is a Co-Founder of CleanWell Company.
Understanding mechanism of action and translating microbiome science into commercially viable therapeutics remains the biggest challenge in this emerging field. With that said, pharma and biotech across many different therapeutic indications and modalities are united in this global effort to bring novel microbiome-based therapies and diagnostics into the clinical domain. This session will include some of the most impactful and promising areas of the microbiome field: